Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2015

View Archived Issues

WOL-074-019 shows efficacy in inflammation models of colitis and psoriasis

Phase I/II and biomarker data of the hypoxia-activated prodrug PR-104 in AML and ALL

Scientists discover divergent urinary metabolic phenotypes between MDD and BD

Galera plans phase II trial of GC-4419 to protect against radiation-induced oral mucositis

VBL Therapeutics plans phase III study of VB-111 plus bevacizumab in recurrent glioblastoma

ImmunoCellular Therapeutics and FDA reach agreement on SPA for ICT-107

KH-176 receives European orphan drug designation for MELAS syndrome

Wilex confirms discontinuation of collaboration between Heidelberg Pharma and Roche

CFDA approves phase I/II/III clinical trials of pirotinib

Dong-A ST to commercialize Acelex in Korea

Merck & Co. and MD Anderson to evaluate pembrolizumab combination therapies for solid tumors

HiFiBiO achieves milestone in Pfizer antibody research collaboration

DIAPH-3 expression predicts tumor response to chemotherapy

Topline results from phase I study of vonapanitase in symptomatic peripheral artery disease

Bioequivalence results announced for an agent for Fabry's disease

Hua Medicine reports phase Ic data on HMS-5552 in type 2 diabetes

LDL-cholesterol reductions observed in phase I study of CAT-2054

Bayer Schering Pharma presents antimitotics

Roche patents new anti-RSV compounds

AbbVie divulges TrKA inhibitors

Confluence Life Sciences introduces TAK1 inhibitors

Boehringer Ingelheim and Circuit Therapeutics collaborate on metabolic disorders

Redx Pharma patents antibacterial agents

HedgePath studies SUBA-Itraconazole in phase IIb study for basal cell carcinoma nevus syndrome

Phase Ib/II trial investigates talimogene laherparepvec with radiotherapy for soft tissue sarcomas

FDA approves Octapharma's WILATE supplement for the management of VWD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...